The use and understanding of CA125 as a tumor marker for ovarian cancer: A questionnaire-based survey

International Journal of Gynecological Cancer

Volumn 18, Issue 3, 2008, Pages 439-445

  Moss, E L ^a   Hollingworth, J ^b   Holland, M ^c   Murphy, D J ^c   Fernando, I ^d   Reynolds, T M ^b  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b QUEEN S HOSPITAL   (United Kingdom)

^c ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CA125; Ovarian cancer; Tumor marker

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CLINICAL PRACTICE; CONSULTATION; COST CONTROL; FALSE POSITIVE RESULT; FEMALE; GENERAL PRACTITIONER; HUMAN; MEDICAL SPECIALIST; OVARY CANCER; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SENSITIVITY AND SPECIFICITY;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CA-125 ANTIGEN; CHI-SQUARE DISTRIBUTION; FEMALE; GREAT BRITAIN; HEALTH CARE SURVEYS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; PROBABILITY; QUESTIONNAIRES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPECIALTIES, MEDICAL; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 43449123302     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01043.x     Document Type: Article

References (25)

1. Bast RC, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. NEJM 1983 309 : 883 7.
2. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 1983 79 : 98 104.
3. Sturgeon C, McAllister EJ. Analysis of HCG. Clinical applications and assay requirements. Ann Clin Biochem 1998 35 : 460.
4. Begent RHJ. The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem 1984 21 : 231.
5. Bast RC, Xu F-J, Yu Y-H, Barnhill S, Zhang Z, Mills GB. CA125: the past and the future. Int J Biol Markers 1998 13 : 179 87.
6. Tuxen MK, Soletormos G, Dombernowsky P. Serum tumour marker CA125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001 84 : 1301 7.
7. Matsuoka Y, Nakashima T, Endo K et al. Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells. Cancer Res 1987 47 : 6335 40.
8. Jhang H, Chuang L, Visintainer P, Ramaswamy G. CA125 levels in the preoperative assessment of advanced uterine cancer. Am J Obstet Gynecol 2003 188 : 1195 7.
9. Chaube A, Tewari M, Singh U, Shukla HS. CA125: a potential tumor marker for gallbladder cancer. J Surg Oncol 2006 93 : 665 9.
10. Miralles C, Orea M, Espana P et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003 10 : 150 4.
11. Moley KH, Massad LS, Mutch DG. Pelvic inflammatory disease. Correlation of severity with CA125 levels. J Reprod Med 1996 41 : 341 6.
12. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. B J Obstet Gynaecol 1990 97 : 922 9.
13. Tingulstad S, Hagen B, Skjeldestad FE et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996 103 : 826 31.
14. McGinley PJ, Kilpatrick ES. Tumour markers: their use and misuse by clinicians. Ann Clin Biochem 2003 40 : 643 7.
15. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005 58 : 308 12.
16. Conover WJ. Practical nonparametric statistics, 2nd edn. New York : John Wiley and Sons, 1980.
17. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997 50 : 1129 36.
18. van der Burg MEL, Lammes FB, Verweij J. CA125 in ovarian cancer. Neth J Med 1992 40 : 36 51.
19. Jacobs IJ, Skates S, Davies AP et al. Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: a prospective cohort study. BMJ 1996 313 : 1355 8.
20. Koc S, Beydili G, Tulunay G et al. Peritoneal tuberculosis mimicking advanced ovarian cancer: a retrospective review of 22 cases. Gynecol Oncol 2006 103 : 565 9.
21. Lipitz S, Grisaru D, Achiron R, Ben-Baruch G, Schiff E, Mashiach S. Spontaneous ovarian hyperstimulation mimicking an ovarian tumour. Human Reprod 1996 11 : 720 1.
22. Guppy AE, Rustin GJS. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 2002 7 : 437 43.
23. Duffy M, McGing P, Mc Sweeny J. Guidelines for the use of tumour markers. Association of clinical biochemists in Ireland. Available at : http://www.iol.ie/∼deskenny/acbi-tmk.html. 2000. [accessed July 2007].
24. MRC clinical trials unit. Available at : http://www.ctu.mrc.ac.uk/ studies/CHORUS.asp. [accessed July 2007].
25. Kudoh K, Kikuchi Y, Kita T et al. Preoperative determination of several serum tumour markers in patients with primary epithelial ovarian cancer. Gynecol Obstet Invest 1999 47 : 52 7.